Biosimilars

Evaluating Biosimilar Programs and Formularies

Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care Plans

Tracking Usage and Monitoring the Impact of Biosimilars

Protocols and Laws for Transitioning to Biosimilars

Transitioning to a Biosimilar Program

Increased Use of Biosimilars

Optimizing Transitions to Biosimilars

Optimizing Transitions to Biosimilars Continued

Integrating AI and Pathway Flexibility to Advance Value-Based Cancer Care: Clayton Irvine, PharmD, MBA, MS

Navigating Biosimilar Mandates and Prior Authorization in a Value-Based Cancer Care Model: Jason Bergsbaken, PharmD, MBA, BCOP

Working With Policy Makers to Effectively Implement Biosimilars

Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars

Optimizing the Implementation of Biosimilars Into Formularies

Examining the Role of Interchangeability in Clinical Practice

Cost Savings Potential Associated With the Use of Biosimilars

How the IRA is Reshaping Biosimilar Adoption

The Road to Biosimilar Adoption: Navigating Interchangeability

The Biosimilar Shift: How PBMs Are Reshaping Formularies

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required

Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient

Biosimilars Are Being Approved but Not Reaching the Market

Progress in the US With Biosimilars, but Opportunities Remain

Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News

Podcast: This Week in Managed Care—Verma on Health Data and Other Health News

The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange

Podcast: This Week in Managed Care—New Voluntary Payment Model and Other Health News